https://ansm.sante.fr/informations-de-securite/xgeva-denosumab-v-risque-de-second-cancer-primitif 2018 false false false France French pharmacovigilance note Denosumab denosumab injections, subcutaneous neoplasms, second primary Advanced Malignant Neoplasm risk assessment bone neoplasms giant cell tumor of bone product surveillance, postmarketing cancer, second primary
--- https://www.e-cancer.fr/Professionnels-de-sante/Facteurs-de-risque-et-de-protection/Second-cancer-primitif 2013 France scientific and technical information risk factor for malignancy risk factors cancer, second primary Second cancer Protective Factors neoplasms, second primary neoplasm, malignant risk factor